Get started
Work

Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Stem Cell Transplant (HSCT) Receiving Defibrotide Treatment: A Post-Hoc Analysis

Year: 2017
Type: article
Abstract: Introduction: VOD/SOS is an unpredictable, potentially life-threatening complication of HSCT conditioning. VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved in the US to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT, and in the EU to treat severe hepatic VOD/SOS post-HSCT. Defibrotide had been available in the US via an expanded-access program.
DOI: 10.1016/j.bbmt.2016.12.178
Authors: Stephan A. Grupp, Angela R. Smith, Brandon M. Triplett, Joseph H. Antin, Leslie Lehmann, Wei Liang, Robin Hume, William Tappe, Paul G. Richardson
Institutions: Children's Hospital of Philadelphia, University of Minnesota, St. Jude Children's Research Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Jazz Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2590185485
FWCI:
Cites:
Cited by:
Related to: 10